Image source: Getty Images.
After providing investors with two regulatory updates related to its nonsense mutation Duchenne muscular dystrophy (nmDMD) drug, Translarna, shares of PTC Therapeutics (NASDAQ: PTCT) fell by 31% as of 12:00 p.m. EDT on Monday.